NCT05583812View on ClinicalTrials.gov

A Study of FB2001 for Inhalation in Healthy Chinese Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 21, 2022

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions
COVID-19 Pandemic
Interventions
DRUG

FB2001 for inhalation

FB2001 once or twice daily inhalation

DRUG

FB2001 for inhalation placebo

FB2001 placebo once or twice daily inhalation

Trial Locations (1)

Unknown

The Third Hospital of Changsha, Changsha

Sponsors
All Listed Sponsors
lead

Frontier Biotechnologies Inc.

INDUSTRY